Karyopharm Therapeutics (NASDAQ:KPTI) Downgraded by Rodman & Renshaw to Neutral

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by Rodman & Renshaw from a “buy” rating to a “neutral” rating in a research report issued on Monday, Benzinga reports.

Several other equities analysts have also issued reports on the stock. Weiss Ratings lowered shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. Robert W. Baird downgraded Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price target for the company. in a research note on Friday, July 31st. HC Wainwright lowered shares of Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a report on Friday, July 31st. Piper Sandler lowered their price objective on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, Wall Street Zen cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $11.50.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock traded down $0.55 during trading hours on Monday, reaching $0.11. The company had a trading volume of 35,936,290 shares, compared to its average volume of 1,565,254. Karyopharm Therapeutics has a 1-year low of $0.09 and a 1-year high of $10.99. The company has a 50 day moving average of $1.22 and a 200 day moving average of $6.02. The firm has a market cap of $2.52 million, a price-to-earnings ratio of -0.01 and a beta of 1.04.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The business had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $32.19 million. As a group, sell-side analysts forecast that Karyopharm Therapeutics will post -4.70 EPS for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

A number of large investors have recently bought and sold shares of the company. Commodore Capital LP purchased a new position in Karyopharm Therapeutics in the 1st quarter valued at approximately $10,862,000. Avidity Partners Management LP raised its position in Karyopharm Therapeutics by 244.6% in the 1st quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock worth $2,583,000 after purchasing an additional 329,175 shares during the period. Squarepoint Ops LLC bought a new position in Karyopharm Therapeutics during the 2nd quarter worth approximately $623,000. Headlands Technologies LLC purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth approximately $118,000. Finally, Bank of New York Mellon Corp bought a new position in Karyopharm Therapeutics in the second quarter worth about $559,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on selective inhibitors of nuclear export (SINE), a class of compounds designed to interfere with the transport of tumor-suppressing proteins and other molecules in cancer cells.

Karyopharm’s leading product is selinexor, marketed in the United States as XPOVIO and in certain international markets as NEXPOVIO.